CureVac ist endlich an der Börse (Seite 749)
eröffnet am 12.08.20 14:50:35 von
neuester Beitrag 23.05.24 14:32:44 von
neuester Beitrag 23.05.24 14:32:44 von
Beiträge: 11.035
ID: 1.329.304
ID: 1.329.304
Aufrufe heute: 753
Gesamt: 995.435
Gesamt: 995.435
Aktive User: 1
ISIN: NL0015436031 · WKN: A2P71U · Symbol: 5CV
3,7440
EUR
+2,69 %
+0,0980 EUR
Letzter Kurs 19:19:54 Tradegate
Neuigkeiten
TitelBeiträge |
---|
09:29 Uhr · wallstreetONLINE Redaktion |
18:30 Uhr · Markus Weingran |
13:00 Uhr · EQS Group AG |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2780 | +53,79 | |
2,1800 | +27,49 | |
0,7000 | +22,79 | |
10.777,50 | +19,75 | |
23,000 | +16,16 |
Wertpapier | Kurs | Perf. % |
---|---|---|
10,551 | -13,94 | |
15,680 | -14,83 | |
46,40 | -15,64 | |
0,8069 | -15,95 | |
1,9100 | -16,96 |
Beitrag zu dieser Diskussion schreiben
könnte die nächsten Tage oder auch schon heute die 80,00 € nehmen
sollte sich endlich aus der seitwärts Richtung veranschieden.
.
.
CUREVAC - Der Chef des Tübinger Biotech-Unternehmens Curevac, Franz-Werner Haas, hält an seinem Ziel fest, seinen Corona-Impfstoff Anfang Juni auf den Markt bringen zu können. Es sei schwer, einen genauen Zeitpunkt zu bestimmen, weil es in der sogenannten Phase-3-Studie mit 35.000 Probanden eine bestimmte Anzahl von Erkrankten geben müsse, bevor sie ausgewertet werden könne. (Stuttgarter Zeitung)
.
Scheinen ordentliche Arbeit zu leisten und nicht übereilt auf dem Markt zu bringen und dann gibt es Schwierigkeiten.
.
Scheinen ordentliche Arbeit zu leisten und nicht übereilt auf dem Markt zu bringen und dann gibt es Schwierigkeiten.
Antwort auf Beitrag Nr.: 67.664.833 von PlanschProtectionTeam am 31.03.21 11:28:28
Warum? AstraZeneca wird weiter geimpft wenn auch in anderer Altersgruppe über 60 Jahre als erst geplant. Zugelassenen CureVac-Impfstoff gibt es weiterhin nicht.
Zitat von PlanschProtectionTeam: ... Alle die dachten CureVac wäre zu spät wurden eines besseren belehrt.
Warum? AstraZeneca wird weiter geimpft wenn auch in anderer Altersgruppe über 60 Jahre als erst geplant. Zugelassenen CureVac-Impfstoff gibt es weiterhin nicht.
Curevac 31.3.2021 - 11.20
Williams -> Kaufsignal
Bollinger -> Kaufsignal
MACD -> Positiv
Williams -> Kaufsignal
Bollinger -> Kaufsignal
MACD -> Positiv
Geholfen haben vermutlich auch die neuerlichen Probleme bei AstraZeneca. Weitere Alternativen sind dringender denn je und CureVac wird diese liefern. Alle die dachten CureVac wäre zu spät wurden eines besseren belehrt.
Die gestrigen Zahlen von BioNTech haben auch unserer CureVac im Kurs geholfen.
Wir sind halt doch eine große Familie.
Wir sind halt doch eine große Familie.
- Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year
- More than 50 million doses are expected to be produced before the end of 2021
- The mRNA-based vaccine will be manufactured at Celonic’s state-of-the-art facility in Heidelberg,
Germany
TÜBINGEN, Germany/ BOSTON, USA/ BASEL, Switzerland – March 30, 2021
CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed bio-therapeutics, today announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.
The parties entered into a commercial supply agreement to produce CureVac’s coronavirus vaccine candidate at Celonic’s state-of-the-art commercial manufacturing facility for biologics and ATMPs, in Heidelberg, Germany. In total Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021. Under the terms of the initial agreement, technology and knowledge transfer is already underway. The commercial supply agreement includes manufacturing of the mRNA drug substance as well as LNP formulation of the bulk drug product.
CureVac reaffirms an expected output capacity of its broad European manufacturing network of up to 300 million doses in 2021.
“Manufacturing of sufficient quantities of vaccine is critical to combating the COVID-19 pandemic,” said Dr. Florian von der Mülbe, Chief Production Officer of CureVac. “With this partnership, we are further extending our integrated European manufacturing network, reinforcing the overall production capacity for our COVID-19 vaccine candidate, CVnCoV.”
“Since the onset of the pandemic, Celonic has committed extensive breadth of complex bio-solutions development expertise and manufacturing resources to this global challenge,” added Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic. “We have invested heavily to support our partners in bringing novel COVID-19 therapeutics and vaccines to patients, at an accelerated pace. Celonic is proud to collaborate with CureVac as part of an expansive manufacturing network in this global fight against COVID-19 by contributing to the production of its mRNA-based COVID-19 vaccine candidate, CVnCoV. With a dedicated and highly motivated team in place, Celonic is well positioned to have produced the first 50 million doses before end of 2021.”
https://www.curevac.com/2021/03/30/celonic-and-curevac-annou…
- More than 50 million doses are expected to be produced before the end of 2021
- The mRNA-based vaccine will be manufactured at Celonic’s state-of-the-art facility in Heidelberg,
Germany
TÜBINGEN, Germany/ BOSTON, USA/ BASEL, Switzerland – March 30, 2021
CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed bio-therapeutics, today announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.
The parties entered into a commercial supply agreement to produce CureVac’s coronavirus vaccine candidate at Celonic’s state-of-the-art commercial manufacturing facility for biologics and ATMPs, in Heidelberg, Germany. In total Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021. Under the terms of the initial agreement, technology and knowledge transfer is already underway. The commercial supply agreement includes manufacturing of the mRNA drug substance as well as LNP formulation of the bulk drug product.
CureVac reaffirms an expected output capacity of its broad European manufacturing network of up to 300 million doses in 2021.
“Manufacturing of sufficient quantities of vaccine is critical to combating the COVID-19 pandemic,” said Dr. Florian von der Mülbe, Chief Production Officer of CureVac. “With this partnership, we are further extending our integrated European manufacturing network, reinforcing the overall production capacity for our COVID-19 vaccine candidate, CVnCoV.”
“Since the onset of the pandemic, Celonic has committed extensive breadth of complex bio-solutions development expertise and manufacturing resources to this global challenge,” added Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic. “We have invested heavily to support our partners in bringing novel COVID-19 therapeutics and vaccines to patients, at an accelerated pace. Celonic is proud to collaborate with CureVac as part of an expansive manufacturing network in this global fight against COVID-19 by contributing to the production of its mRNA-based COVID-19 vaccine candidate, CVnCoV. With a dedicated and highly motivated team in place, Celonic is well positioned to have produced the first 50 million doses before end of 2021.”
https://www.curevac.com/2021/03/30/celonic-and-curevac-annou…
dann hoffen wir mal das es bald was wird
18:30 Uhr · Markus Weingran · CTS Eventim |
13:00 Uhr · EQS Group AG · CureVac |
13:00 Uhr · EQS Group AG · CureVac |
09:29 Uhr · wallstreetONLINE Redaktion · Pfizer |
17.05.24 · Sharedeals · CureVac |
08.05.24 · wO Chartvergleich · Plug Power |
26.04.24 · Sharedeals · CureVac |
24.04.24 · dpa-AFX · CureVac |
24.04.24 · Accesswire · CureVac |
24.04.24 · Accesswire · CureVac |
Zeit | Titel |
---|---|
18.05.24 | |
20.03.24 |